Form 4: Avidity Biosciences CSO Files Form 4 for Pre-Planned Stock Option Exercise and Sale

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, has filed a Form 4 detailing a pre-planned exercise of stock options and subsequent sale of 20,000 common shares on June 11, 2025, under a Rule 10b5-1 trading plan.

Summary

• W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences, Inc. (RNA), filed a Form 4 with the SEC on March 12, 2025.
• The filing reports a planned transaction scheduled for June 11, 2025.
• Mr. Flanagan intends to exercise 20,000 stock options at an exercise price of $14.22 per share.
• Concurrently, he plans to sell 20,000 shares of common stock at a weighted-average price of $32.8847 per share, with individual transaction prices ranging from $31.99 to $33.60.
• These transactions are being conducted pursuant to a Rule 10b5-1 trading plan that was adopted on June 12, 2024.
• Following these reported transactions, Mr. Flanagan will beneficially own 80,195 shares of common stock directly and 96,500 stock options directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While an insider sale can sometimes be viewed negatively, the fact that it is a pre-planned Rule 10b5-1 transaction mitigates concerns about opportunistic selling. The significant profit realized from the option exercise is a positive for the insider.

Positives

• The transaction is pre-planned under a Rule 10b5-1 trading plan, which indicates the sale is not based on immediate, non-public information and is a routine part of an executive's compensation management.
• The sale price of $32.8847 per share is significantly higher than the option exercise price of $14.22 per share, indicating a substantial profit for the insider on these shares.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

This filing represents a routine insider transaction for an executive managing their equity compensation. While it does not directly reflect broader industry trends, insider activity is a data point closely monitored by investors within the biotechnology sector.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the pre-planned nature under a 10b5-1 plan helps to alleviate concerns about the insider's confidence in the company. The transaction itself does not directly impact company operations or financial health beyond the insider's equity stake.

Key Dates

Recommendation

Keywords

Avidity Biosciences, RNA, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Rule 10b5-1 Plan, W. Michael Flanagan, Chief Scientific Officer, Biotechnology, SEC Filing